Cargando…
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
BACKGROUND: Adjuvant therapy decisions in early breast cancer are based on accurate risk assessment. Urokinase plasminogen activator (uPA) and plaminogen activator inhibitor-1 (PAI-1) have been the first biomarkers in hormone receptor (HR) positive breast cancer to reach highest level of evidence. T...
Autores principales: | Ettl, Johannes, Klein, Evelyn, Hapfelmeier, Alexander, Grosse Lackmann, Kirsten, Paepke, Stefan, Petry, Christoph, Specht, Katja, Wolff, Laura, Höfler, Heinz, Kiechle, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587293/ https://www.ncbi.nlm.nih.gov/pubmed/28877230 http://dx.doi.org/10.1371/journal.pone.0183917 |
Ejemplares similares
-
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019) -
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020) -
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves
por: Kochtebane, Najlah, et al.
Publicado: (2014) -
Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
por: Märkl, Bruno, et al.
Publicado: (2019) -
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999)